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SuMMAry “Non-Aromatic Very rich in Steranes” (NAVS) naphthalan is 
a purified natural oil derivative, abundant in steranes (geogenic „ste-
roids“). The purpose of this study was to evaluate the effectiveness of 
NAVS in the treatment of oral lichen planus (OLP) and recurrent aph-
thous stomatitis (RAS). We used NAVS oil in adhesive paste in 11 pa-
tients with clinically and histologically proven OLP (open label), and in 7 
patients with RAS (double blind randomized; topical betamethasone in 
adhesive paste used as control). The severity of the OLP lesions was ob-
jectively scored. The number and diameter of RAS lesions were assessed 
on days 0, 3, and 5. The intensity of pain and discomfort was determined 
using visual analogue scale (VAS) and  „Oral health impact profile“ (OHIP-
14) before and after therapy. OLP cumulative activity scores on days 0 
and 28 were 101.5 and 48.5, respectively (t=5.99; P=0.0001). Using NAVS 
for 28 days resulted in 52.2% overall clinical improvement. Cumulative 
OHIP-14 scores on days 0 and 28 were 210 and 142, respectively (t=5.65; 
P=0.0002). Out of a total of 7 patients with RAS, 4 of them were treated 
with NAVS and 3 with topical corticosteroids. There were no statistically 
significant differences in improvement rate between the two groups 
(lesion number (day 3 P=0.29; day 5 P=0.32); lesion diameter (day 3 
P=0.64; day 5 P=0.74)).  NAVS successfully reduced the clinical signs and 
symptoms of OLP, and reduced the number, diameter, and symptoms in 
patients with RAS, statistically comparable with corticosteroids. 
KeywOrDS: naphthalan, non-aromatic; therapy, topical; lichen planus, 
oral; aphthous stomatitis, recurrent; oral health impact profile; visual 
analogue scale 
INTrODuCTION
Special types of mineral oils have been used for 
centuries as medicinal agents in wound healing and 
management of skin diseases (1). Nonaromatic naph-
thalan (NAVS) is a purified natural oil derivative, abun-
dant in steranes (geogenic „steroids“), which were 
indicated as potential bioactive agents with healing 
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effects (2-8). Some studies indicated the structural 
similarity of geogenic steranes to bioactive natural 
and synthetic steroids (vitamins, steroid hormones) 
(8). Owing to these properties, this product has a 
potential role in treatment of oral mucosal diseases. 
Based on the literature data, NAVS was studied very 
extensively both in vitro and in vivo in animal models 
and in humans (5,7-9). Studies of genotoxicity, muta-
genicity, microbiological safety, the content of heavy 
metals and non-metals, and irritability showed appli-
cation was completely safe, regardless of the dose (4). 
Previous clinical studies in dermatological patients 
demonstrated favorable therapeutic effect, with-
out local or systemic side effects (5,10). The origin of 
NAVS is an ordinary naphthalan, which has been used 
for decades as balneotherapy in the “Naftalan” Spe-
cial Hospital for Medical Rehabilitation Ivanić Grad, 
without side effects and impact on biochemical or 
hematological parameters (5,9). 
Today, topical corticosteroids are the mainstay of 
the management of oral immune mediated diseases. 
Corticosteroids commonly used in the treatment of 
the oral mucosal diseases are betamethasone dipro-
pionate, clobetasol propionate, fluocinonide, and 
triamcinolone acetonide, the last one being often 
applied by intralesional injections in cases of erosive 
oral lichen planus (OLP) and for major aphthous ulcers 
(11). Carrozzo and Gandolfo (12) have listed empiri-
cal treatment modalities used for oral lichen planus, 
which besides those mentioned above include: a) 
corticosteroids (topical: betamethasone phosphate, 
betamethasone valerate, fluocinolone acetonide, 
fluticasone propionate, hydrocortisone hemisuc-
cinate; systemic: prednisone, methylprednisolone); 
b) retinoids (topical: fenretinide, isotretinoin, tazaro-
tene, tretinoin; systemic: acitretin, etretinate, isotreti-
noin, temarotene, tretinoin); c) immunosuppresive 
agents (systemic azathioprine, topical and systemic 
cyclosporine, pimecrolimus, and tacrolimus), d) oth-
ers (amphotericin A, basiliximab, diethyldithiocar-
bamate, dapsone, doxycycline, enoxaparin (heparin 
derivative), glycyrrhizin, griseofulvin, hydroxychloro-
quine sulphate, interferon, levamisole, magnetism, 
mesalazine, phenytoin, photopheresis, psychothera-
py, PUVA, reflexotherapy, surgery, and thalidomide). 
Additionally, mycophenolate mofetil has shown to 
be beneficial in very severe cases of mucocutane-
ous involvement recalcitrant to other forms of treat-
ment (13). However, in OLP and recurrent aphthous 
stomatitis (RAS), topical corticosteroids are indicated 
as the first line of treatment to reduce inflammation 
and pain, generally without causing systemic adverse 
effects (14,15). The risks of short-term use of topical 
corticosteroids are clinically insignificant, while their 
long-term use is not recommended because of side 
effects, e.g. mucosal atrophy, secondary candidal in-
fection, possible systemic absorption, and suppres-
sion of the adrenal glands (16). Considering these 
side effects of prolonged standard therapy and the 
frequent need for continuous treatment of chronic 
and recurrent oral mucosal diseases, the purpose 
of this study was to evaluate NAVS as an alternative 
treatment modality. The aim was to assess NAVS ef-
ficacy on clinical and symptomatic improvement of 
OLP and RAS, and to compare it with topical cortico-
steroids in patients with RAS.
MATerIAL AND MeTHODS
The study was conducted at the Department of 
Oral Medicine, University of Zagreb School of Dental 
Medicine. We included 18 patients in total, of which 
11 patients with oral lichen planus (OLP) and 7 with 
the diagnosis of recurrent aphthous stomatitis (RAS). 
This study was approved by the Ethical Committee 
of the University of Zagreb School of Dental Medi-
cine, and informed consent was obtained from every 
patient. The part of the study pertaining to patients 
with OLP was conducted in an open label manner. 
Seven patients with RAS were included in the dou-
ble-blind randomized clinical trial comparing the ef-
fects of NAVS with topical steroids. Exclusion criteria 
were: patients younger than 18 years, hematological 
deficiencies, diseases of the hepatobiliary system, li-
chenoid reactions to amalgam and drugs, pregnancy, 
inflammatory bowel disease, immune dysfunction, 
current concomitant systemic or local anti-inflamma-
tory therapy (corticosteroids, NSAIDs, etc.) (16-19). 
Routine hematological and biochemical tests were 
performed and data were collected through medical 
history. Inclusion criteria of this study were: patients 
with clinically and histologically proven OLP (20) and 
patients with RAS (according to Lehner, 2 or more 
episodes per year) (21). All patients involved in the 
study had the active phase of the disease at the start 
of their therapy.
NAVS formulation was prepared by mixing NAVS 
naphthalan oil and Stomahesive powder (ConvaTec) 
in volume ratio 2:1.
OLP patients were treated with topical NAVS oil in 
adhesive paste, three times per day for 4 weeks. The se-
verity of the OLP lesions was objectively scored accord-
ing to Pibooniyom et al. (22) on days 0 and 28 of the 
therapy. Participating clinicians were previously adjust-
ed for inter- and intra-observer reliability for OLP clini-
cal scoring. One clinician assessed patients on admis-
sion and the other after 28 days of treatment, in order 
to minimize the inherent bias of an open label study.
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RAS patients were randomly divided into two 
groups: test and control group. The test group was 
treated with topical NAVS oil in adhesive paste, three 
times per day for 1 week, and the control group was 
treated with 0.05% betamethasone dipropionate oint-
ment (Beloderm, Belupo) in adhesive paste (mixed 
1:1), three times per day for 1 week. The number and 
diameter (in millimeters, using periodontal calibrated 
probe) of RAS lesions was assessed on days 0, 3, and 
5 (23). In all patients, the intensity of pain and dis-
comfort was determined using visual analogue scale 
(VAS) and „Oral health impact profile“ (OHIP-14) be-
fore and after therapy (23,24). A photograph of the le-
sion was taken before and after the therapy. Random-
ization of RAS patients was performed by a registered 
nurse, and the assessing clinician was blinded to as-
signed treatment modality. After completion of the 
investigation, the randomization code in RAS cases 
was opened. Effects of the therapy was compared be-
tween groups (NAVS and corticosteroids) by t-test for 
independent samples. T-test for dependent samples 
was used to assess the effect of therapy in patients 
with OLP (before and after treatment).
reSuLTS
OLP patients
The mean values of OLP activity scores on days 0 
and 28 of the therapy are presented in Table 1.
T-test for dependent samples showed a statistical-
ly significant reduction of hyperkeratosis, erythema, 
and ulceration after administration of NAVS 3 times 
per day for 28 days. OLP cumulative activity scores of 
all patients on days 0 and 28 were 101.5 and 48.5, re-
spectively (t=5.99; P=0.0001). Using NAVS for 28 days 
resulted in 52.2% overall clinical improvement. 
OLP activity scores for each patient before and at 
the end of treatment are presented in Figure 1.
Figures 2 and 3 show clinical improvement in 2 
OLP cases after treatment with NAVS.
Oral health related quality of life assessment was 
determined using OHIP-14 on day 0 and 28. Cumula-
tive OHIP-14 scores of all patients with OLP on days 
0 and 28 were 210 and 142, respectively (t=5.65; 
P=0.0002). Using NAVS for 28 days resulted in 32.4% 
overall improvement of OHIP-14. Figure 4 presents 
OHIP-14 scores for each patient before and at the end 
of treatment. 
Daily subjective symptoms were assessed using 
VAS. A higher value indicates a more severe painful 
condition. Results are shown in Table 2. Cumulative 
amount of VAS on days 0 and 28 were 257 and 62, 
respectively. This is a reduction of 75.88%.
rAS patients
Out of total 7 patients with RAS, 4 of them were 
allocated to treatment with NAVS and 3 to treatment 
with topical corticosteroids. There were no statisti-
cally significant differences in improvement rates 
between the two groups expressed by a percentage 
of the residual number of lesions in all patients (day 
3 P=0.29; day 5 P=0.32) and percentage of residual 
lesion diameter (day 3 P=0.64; day 5 P=0.74) of all 
patients. The percentages of the residual number of 
lesions are presented in Table 3 and Figure 5.
Figure 6 shows a case of a patient with treated with 
NAVS, and Figure 7 a case of a patient with RAS treated 
with corticosteroids. There is a similar pattern of im-
provement in both patients after 5 days of treatment.
The percentages of residual lesion diameter are 
presented in Table 4 and Figure 8.
Figure 1. OLP activity scores for each patient before 
and at the end of treatment (on day 0 and day 28).
Table 1. OLP Activity score on days 0 and 28 and t-test for dependent samples (t=5,99, P=0,0001)
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 N Mean Median Minimum Maximum Variance Std.Dev. Std.Err.
OLP activity score 0 11 9.23 10.00 4.00 12.50 8.47 2.91 0.88
OLP activity score 28 11 4.41 5.00 1.50 8.50 5.19 2.28 0.69
 Mean Std.Dv. N Diff. Std.Dv. t df p
OLP activity score 0 9.23 2.91  
OLP activity score 28 4.41 2.28 11 4.82 2.67 5.99 10 0.000134
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Subjective symptoms were assessed using VAS 
before and 7 days after beginning of therapy. A high-
er value indicates a more severe painful condition. No 
statistically significant differences in VAS were found 
between two groups (P=0.97) (Figure 9). No adverse 
reactions were noted.
DISCuSSION
Currently, topical steroids are the “gold standard” 
for treatment of many immune mediated oral diseas-
es, including those included in this study. Because of 
the chronic and/or recurrent nature of those diseases, 
topical steroid usage often needs to be long-lasting, 
sometimes even lasting for years. However, topical 
steroid long-term usage is limited due to mucosal 
Figure 2. Patient with OLP on day 0 (a and b) and on day 28 (c and d) of NAVS treatment. Initial erythema has 
decreased.
Figure 3. Patient with OLP on day 0 (a) and on day 28 (b) of NAVS treatment. Initial erythema and mucosal „at-
rophy“ has decreased.
Table 2. VAS on days 0 (1st week 1st day) and 28 (4th week 7th day) in patients with OLP and results of t-test 
for dependent samples (t=4,16, P=0.002)
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 Mean Std.Dv. N Diff. Std.Dv. t df p
1st week 1st day 23.36 13.84  
4th week 7th day 5.64 10.03 11 17.73 14.11 4.17 10 0.001925
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Table 3. The percentage of the number of residual aphthous lesions on days 3 and 5 per group and statisti-
cal comparison between groups 
atrophy, oral candidiasis, systemic absorption, and 
adrenal suppression (16). Lo Muzio et al. reported 
that topical administration of 0.05% clobetasol pro-
pionate applied in different vehicles gave significant 
remission of the OLP and RAS lesions, but they also 
reported oral candidiasis occurring in 7 out of 18 pa-
tients treated with clobetasol in an adhesive denture 
paste (16). The persistent contact of topical steroids 
with oral mucosa probably causes local immunosup-
pression and leads to candida infection. Therefore, 
Carbone et al. proposed topical corticosteroids in 
association with miconazole and chlorhexidine for 
the long-term management of atrophic-erosive oral 
lichen planus, which is useful and safe prophylaxis 
against oropharyngeal candidiasis (25). Gonzalez-
Moles et al. also found clobetasol 0.05% mouthwash 
effective for the treatment of severe oral erosive lichen 
planus lesions. In a 48-week period they observed 
93.3% total recovery, but five patients suffered from 
adverse effects (hirsutism and moon face) between 
Figure 4. OHIP-14 scores for each patient with OLP 
before and at the end of treatment (on day 0 and day 
28).
Figure 5. Patient with RAS on day 0 (a and b)and on day 5 (c and d) of NAVS treatment. Size of lesions in lower 
and upper vestibular areas has decreased in 5 days of treatment, similar to betamethasone treatment, as shown 
in Fig. 6.
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% residual number Group Mean Minimum Maximum Std.Dev. t p
day 3
NAVS 100.00 100.00 100.00 0.00
1.20 0.29
cortico 88.89 66.67 100.00 19.25
day 5
NAVS 25.00 0.00 50.00 28.87
-1.10 0.32
cortico 44.44 33.33 50.00 9.62
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% residual size Group Mean Minimum Maximum Std.Dev. t p
day 3
NAVS 46.82 20.00 77.27 23.83
-0.50 0.64
cortico 54.29 42.86 60.00 9.90
day 5
NAVS 8.07 0.00 27.27 13.02
-0.35 0.74
cortico 10.87 5.00 14.29 5.11
week 4 and week 6 of treatment, accounting for sys-
temic absorption (26). Other rare adverse effects were 
also reported, such as dry mouth, bad taste and smell, 
swollen mouth, and nausea (27).
In contrast, none of the aforementioned adverse 
reactions were observed in our patients treated with 
topical NAVS in adhesive paste, three times per day 
for 4 weeks. These results indicate safe long lasting 
usage of topical NAVS oil in the treatment of oral mu-
cosal diseases, especially in chronic oral diseases such 
as OLP. Administration of NAVS also showed a statisti-
cally significant (P=0.0001) reduction of hyperkerato-
sis, erythema, and ulceration, as well as marked im-
provement of subjective symptoms associated with 
OLP. These encouraging results indicate that NAVS is 
a potential alternative to corticosteroids in treatment 
of oral mucosal diseases. Prophylactic administration 
of antifungal drugs is also not required. Out of a to-
tal of 7 patients with RAS (double-blind randomized 
clinical trial), 4 of them were treated with NAVS and 
3 with topical betamethasone adhesive paste, with-
out adverse effects. Short-term application of topical 
corticosteroids does not cause side effects. In cases 
of RAS, when recurrence frequency is not high, short 
time usage is indicated, and we do not foresee any 
occurrence of the abovementioned adverse effects. 
However, there are RAS cases with extremely high 
or constant eruption frequency, in which we need 
Figure 7. Reduction of the number of aphthous le-
sions (expressed in percentages) on days 3 and 5 (dan 
= day; % res numb = percentage of residual number 
of lesions).
Table 4. The percentage of residual aphthous lesion diameter on days 3 and 5 per group and statistical 
comparison between groups
Figure 8. Reduction of the diameter of aphthous le-
sions (expressed in percentages) on days 3 and 5 (dan 
= day; %res size = percentage of residual size on days 
3 and 5).
Figure 6. Patient with RAS on 0 (a) and on day 5 (b) of treatment with topical bethamethasone dipropionate. 
Size of lower lip lesions has decreased in 5 days of treatment, similarly to NAVS treatment as in Fig. 5.
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to consider prolonged corticosteroid usage, which 
would eventually lead to adverse reactions. In this 
group of patients, a treatment modality devoid of 
adverse effects is required. We did not observe sta-
tistically significant differences in improvement rate 
between two groups according to the lesion number 
and lesion diameter. No statistically significant differ-
ences were found in VAS between the two groups of 
patients with RAS. Both clinically and symptomati-
cally, NAVS seem comparable to topical steroid treat-
ment of RAS. Previously published studies have tried 
to explain the bioactivity of naphthalan. Thaci et al. 
demonstrated its antiproliferative effect on keratino-
cytes and increased differentiation rate (3). Vržogić et 
al. showed its significant antiproliferative activity and 
ability to decrease immunocompetent cell count and 
reduce epidermal hyperplasia in patients with psoria-
sis vulgaris (28). In another study, Vržogić et al. dem-
onstrated significant decrease of neovascularization 
rate in psoriatic lesion treated with naphthalan (29). 
Krnjević et al. also investigated the effects of naph-
thalan on intraepidermal proliferative activity, epi-
dermal and dermal CD4 and CD8 lymphocyte count, 
intraepidermal apoptotic cell count, and antiangio-
genic activity (9,10). Alajbeg et al. have demonstrated 
not only that NAVS does not cause the proliferation 
of the squamous cell carcinoma (SCC), but also that 
NAVS in vitro inhibits proliferation of SCC VII cells and 
delays tumor growth in vivo in the murine model, 
compared to controls (7). In addition, we have ob-
served its antineoangiogenic properties in a murine 
oral squamous cell carcinoma model (30). Because 
of its inhibitory effect on intraepidermal proliferative 
activity, on intraepidermal and dermal inflammatory 
cells, as well as on neoangiogenesis, we can extrapo-
late those findings to our observed favorable results 
on OLP and RAS, as both conditions are characterized 
by immune cells proliferation, and OLP is additionally 
characterized by epithelial and endothelial prolifera-
tion (31).
There are various different naphthalan formula-
tions available, and they are all derivative of natu-
ral oil. There are many hydrocarbon constituents, 
and they can not be analyzed completely. However, 
some important groups have been characterized 
(2,4-6,8,32). All naphthalan products contain steranes 
as a minor group of compounds, but NAVS formula-
tion contains increased amount of steranes (thus the 
name “... Very rich in Steranes”).
Steranes are considered to be the bioactive com-
ponents in naphthalans used in the management 
of epithelial hyperproliferative and inflammatory 
diseases such as psoriasis (5). Their prospective in-
dications may also include other immune mediated 
inflammatory conditions such as atopic dermatitis, 
rheumatoid and psoriatic arthritis (33), and now also 
oral lesions. Besides steranes, there are plenty of other 
cycloalkanes in naphthalans. Isoalkanes are present 
in abundance, while normal alkanes and compounds 
containing functional groups are present in low con-
centrations. Brown naphthalans contain aromatics of 
different structures and concentrations, making up to 
half of the content (32,34). As aromatics include po-
tentially carcinogenic compounds, a common goal 
is to use naphthalan products containing as few aro-
matics as possible (34). Potentially carcinogenic poly-
cyclic aromatics have been completely removed from 
NAVS (thus the name “Non-Aromatic...”), making it a 
safe product. To prove this, we have previously pub-
lished UV/VIS spectra of NAVS, displaying the light 
absorption of A=0.0291 at 275 nm, which is remark-
ably lower than DAB 10 requirements for low-(non-) 
aromatic character required for medicinal paraffinic 
preparations (A=0.2454) (8). NAVS is a transparent, 
colorless, and odorless oil with a very mild pine tree 
fragrance, and thus applicable for oral mucosa. It is 
very important to bear in mind the potentially malig-
nant nature of OLP. As an example, Australian Cancer 
Registry data reveal that approximately 0.2% OLP pa-
tients develop intra-oral carcinoma each year, com-
pared with approximately 0.005% Australian adults 
(35). This indicates that OLP is a potentially malignant 
oral disorder. Thus, it is particularly important to be 
sure that all potentially carcinogenic polycyclic aro-
matics have been removed from the product that we 
are applying to treat OLP. Additionally, keeping in 
mind that NAVS has exhibited antiproliferative and 
antiangiogenic effects in squamous cell cancer mod-
els, one could speculate about its chemopreventive 
properties (7,30).
Figure 9. VAS score before the 1st application (VAS 0 = 
100%) and after 7 days of treatment (VAS 1 = residual 
%) in patients with RAS. Blue = patients allocated to 
NAVS; red = patients allocated to corticosteroids.
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Our preliminary data were obtained using two dif-
ferent study designs: open label for OLP, and double 
blind randomized for RAS. This is the result of a pro-
cess in which we primarily wanted to obtain basic 
preliminary data on whether NAVS affects the clinical 
and symptomatic course of OLP at all; hence the open 
label design. Encouraged by the results, we switched 
to a randomized controlled trial design for RAS, and 
were able to recruit a small group of patients. Pre-
liminary results of this small pilot study indicate a 
good performance of NAVS in the treatment of OLP 
and RAS, statistically comparable with corticosteroid 
therapy for the latter. These results are encourag-
ing, and undertaking a full scale clinical study seems 
worthwhile.
CONCLuSION
NAVS successfully reduced the clinical signs and 
symptoms of OLP; it reduced the number, lesion di-
ameter, and symptoms in patients with RAS, statisti-
cally comparable with corticosteroids. These results 
indicate good performance of NAVS as a potential 
alternative to corticosteroids in treatment of oral mu-
cosal diseases.
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